Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what data they are gathering on countries currently implementing immunisation programmes for infant respiratory syncytial virus regarding (1) acceptance and uptake, and (2) hospitalisations.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK Health Security Agency continues to monitor international reporting. In the United States, as of 31 January 2024, maternal immunisation was 17.9%. By February 2024, 43% of infants under eight months old had received a dose of nirsevimab.
In Galicia, Spain, 92.9% of 5,357 infants born between 25 September 2023 and 4 February 2024 had nirsevimab, plus 79.7% of 5,823 in a catch-up programme. The peak of hospitalisation rate in infants under six months old was 102 per 100,000, for season 2023 to 2024 during the week starting 27 November 2023 compared to a median of 776 for seasons 2017 to 2018, 2018 to 2019 and 2019 to 2020, peaking during the first week of January 2024.
In Luxembourg, 84% of 1,524 infants born in hospital between early October and mid-December 2023 received nirsevimab. Luxembourg observed a decrease in hospitalisation in infants under six months old of 69% between the 2022 to 2023 and 2023 to 2024 respiratory syncytial virus seasons.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, with reference to declining immunisation rates in the UK, what level of prioritisation the Department of Health and Social Care and the UK Health Security Agency are giving to the adoption of new immunisation programmes with high uptake.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The introduction and adoption of new immunisation programmes and achieving high uptake across all immunisation programmes remains a high priority for the Government. We achieve high uptake for both life-course and seasonal vaccinations, with over 90% for pre-school diphtheria, tetanus, and pertussis and among the highest in the world for flu vaccination. The NHS COVID-19 vaccination programme has been the biggest vaccine drive in the history of the National Health Service, implementing the largest volume of new vaccines in the shortest time, and repeatedly with boosters. 157.5 million COVID-19 vaccinations were delivered in England from December 2020 to the end of January 2024. However, over the last decade, performance across routine immunisation programmes has been in decline and continued variation in uptake and coverage between different communities reflects wider health inequalities.
In response to these challenges, the NHS vaccination strategy builds on lessons learnt from the pandemic and the success of our routine immunisation programmes. It aims to maximise uptake and coverage of vaccinations across all communities, improving uptake to save more lives.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they intend to license the drug Lecanemab for the treatment of dementia and Alzheimer’s disease; and if so, when.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency will review any marketing authorisation application received, and will consider the drug with regard to quality, safety and efficacy. We do not comment on application status or applications in progress, until a full and timely decision is made with consideration of the recommendation of Commission on Human Medicines as needed. We continue to advise that patients consult with their respective healthcare professionals regarding treatment and management options for dementia and Alzheimer’s disease.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department for Work and Pensions:
To ask His Majesty's Government when they will respond to the report from the Parliamentary and Health Service Ombudsman Women’s State Pension age: our findings on injustice and associated issues laid before Parliament on 21 March.
Answered by Viscount Younger of Leckie - Parliamentary Under-Secretary (Department for Work and Pensions)
In laying the report before Parliament at the end of March, the Ombudsman has brought matters to the attention of this House, and a further update to the House will be provided once the report's findings have been fully considered.